The Peptide Encyclopedia

A small-molecule NNMT inhibitor (not a peptide) studied in preclinical metabolic research; included for completeness as it is commonly grouped with research peptides.

A modified fragment of human growth hormone (176-191) investigated for fat-metabolism effects; failed to show significant weight-loss efficacy in trials.

A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied extensively in animal models for tissue-healing effects; no completed human efficacy trials exist.

A porcine-brain-derived peptide preparation marketed in some countries and studied in stroke and dementia trials; not FDA-approved.

A long-acting growth-hormone-releasing hormone analog. The DAC variant was studied in early human pharmacokinetic trials.

An angiotensin-IV-derived peptide studied in preclinical models for synaptogenesis and cognition; no human approval.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied in Russian research for effects on the pineal gland and telomerase; human evidence is limited.

A copper-binding tripeptide present naturally in human plasma. Widely used in topical cosmetic formulations; studied for skin and wound-related effects.

A growth-hormone-releasing peptide and ghrelin-receptor agonist used as a diagnostic agent for growth-hormone deficiency in some countries.

A first-generation growth-hormone-releasing hexapeptide and ghrelin-receptor agonist studied for GH stimulation and appetite effects.

A potent synthetic growth-hormone-releasing hexapeptide studied for GH release and cardiovascular effects in early research.

A mitochondrial-derived peptide studied for cytoprotective and metabolic signaling roles in aging research.

A selective growth-hormone secretagogue (ghrelin-receptor agonist) studied for its ability to stimulate growth-hormone release with minimal effect on cortisol or prolactin.

A fragment of the kisspeptin neuropeptide studied in human reproductive-endocrinology research for its role in gonadotropin release.

A tripeptide fragment of alpha-melanocyte-stimulating hormone studied for anti-inflammatory activity in preclinical models.

An investigational peptide studied as a tight-junction regulator for celiac disease in human clinical trials; not approved.

A synthetic melanocortin agonist studied for skin pigmentation and sexual function. Sold illegally in many regions; associated with notable safety concerns including melanoma risk discussion.

A modified, stabilized fragment of growth-hormone-releasing hormone (1-29) studied alongside ghrelin-receptor agonists in research settings.

A mitochondrial-derived peptide studied for roles in metabolic regulation, insulin sensitivity, and exercise physiology.

A ciliary-neurotrophic-factor-derived peptidomimetic studied in preclinical neurodegeneration models; not approved for human use.

A melanocortin receptor agonist approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women.

An investigational triple GIP/GLP-1/glucagon receptor agonist in late-stage clinical trials for obesity; not yet approved.

A synthetic analog of the endogenous peptide tuftsin, studied in Russia for anxiolytic and nootropic effects.

A GLP-1 receptor agonist approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). One of the most rigorously trialed metabolic drugs.

A synthetic peptide derived from adrenocorticotropic hormone fragment (4-10), studied in Russia for neuroprotective and cognitive effects.

A growth-hormone-releasing hormone analog historically used in diagnostic testing of pituitary function; once marketed as Geref.

A synthetic peptide related to thymosin beta-4, a naturally occurring actin-regulating protein. Studied in preclinical models of tissue repair; human clinical evidence is limited.

A stabilized growth-hormone-releasing hormone analog approved (as Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy.

A thymus-derived polypeptide preparation studied in Russia for immunomodulatory effects in older adults.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with large phase-3 trial programs.